Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
InflaRx ( (IFRX) ) has issued an update.
InflaRx N.V. announced the initiation of a Phase 2a clinical trial for its oral C5aR inhibitor, INF904, aimed at treating chronic spontaneous urticaria (CSU) and hidradenitis suppurativa (HS). The study will involve 75 patients and assess multiple dosing regimens over a four-week treatment period. The trial aims to gather safety and pharmacokinetic data and measure clinical benefits, with results expected by mid-2025. This development positions INF904 as a potential best-in-class anti-inflammatory treatment with a significant market opportunity, addressing unmet needs in CSU and HS, and potentially expanding into other immuno-inflammatory conditions.
More about InflaRx
InflaRx N.V. is a biopharmaceutical company that develops anti-inflammatory therapeutics focused on the complement system, specifically targeting the C5a and C5aR pathways. Founded in 2007, the company offers innovative treatments for inflammatory diseases, with its lead product candidate being vilobelimab, an anti-C5a monoclonal antibody. InflaRx operates in Jena and Munich, Germany, and Ann Arbor, Michigan, USA.
YTD Price Performance: 30.67%
Average Trading Volume: 246,497
Technical Sentiment Consensus Rating: Sell
Current Market Cap: $125.4M
For an in-depth examination of IFRX stock, go to TipRanks’ Stock Analysis page.
